Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 17.24%, which has investors questioning if this is right time to buy.

ACR-2316 was uniquely designed by AP3 to overcome the limitations of current WEE1 and PKMYT1 inhibitors ... known as ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

ACR-368, specifically targeting CHK1/2i, and ACR-2316, aimed at WEE1/ PKMYT1i, are central to Acrivon’s pipeline and are being closely watched by investors and analysts alike for their potential ...

Many variations on this as combo therapy of chk1 and Pd-1 of great importance ... to a deal both development of the CHK1 inhibitor and Wee1 inhibitor were halted? This at the time when GSK pushed ...

Acrivon is currently advancing its lead candidate, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...